Research News
Strukturing Active Ingredient Research
Increasing development costs in the pharmaceutical industry caused active ingredient research to stagnate for a considerable time now. Yet these days, new active ingredients are more necessary than ever before as chronic and complex diseases as well as infection diseases that are almost impossible to treat occur more and more often. Together with external partners, the Helmholtz Health Centres intend to pool their wide-ranging cross-disciplinary basic research and existing competences in the field of active ingredient research and to jointly create a highly modern chemical-biological platform. With up to 3.5 million Euro funding per year from the Joint Initiative for Research and Innovation this will result in building a unique, long-term structure in active ingredient research for developing new treatments both of the most important common conditions and of rare diseases.
"In order to be able to further develop therapies in the most efficient manner possible, chemical and clinical questions already need to be included in biological basic research at a very early stage", says Dr Ronald Frank, coordinating spokesman of the Helmholtz active ingredient research. "The future close cooperation between all partners and the pooling of competences is to result in qualitative and quantitative optimisation of active ingredient research. Consequently, a larger number of high-quality active ingredient candidates for clinical applications with considerable medical requirements can be provided and transferred to further pharmaceutical development."
Helmholtz Active Ingredient Research Partners
German Cancer Research Centre (DKFZ)
German Centre for Neurodegenerative Diseases (DZNE)
Helmholtz Centre for Infection Research (HZI) with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
Helmholtz Zentrum München – German Research Centre for Environmental Health
Max Delbrück Centre for Molecular Medicine (MDC) Berlin-Buch
Research Centre Jülich with the external partners European Molecular Biology Laboratory (EMBL), Leibniz-Institut für Molekulare Pharmakologie (FMP) and the Technical University Munich (TUM).
